
|Articles|May 29, 2020
ASCRS 2020: Clinical trial results of KP1-121 0.25% for dry eye treatment
Author(s)Alex Delaney-Gesing
Advertisement
Edward Holland, MD, director of Cornea Services at Cincinnati Eye Institute, speaks with Ophthalmology Times' David Hutton on the results of a clinical trial using KP1-121 0.25% (loteprednol etabonate) for dry eye treatment during the 2020 ASCRS virtual meeting.
Advertisement
Latest CME
Advertisement
Advertisement




















